Mohamed Altai
Mohamed Altai
Verified email at
Cited by
Cited by
Pretargeted imaging and therapy
M Altai, R Membreno, B Cook, V Tolmachev, BM Zeglis
Journal of Nuclear Medicine 58 (10), 1553-1559, 2017
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties
H Wållberg, A Orlova, M Altai, SJ Hosseinimehr, C Widström, J Malmberg, ...
Journal of Nuclear Medicine 52 (3), 461-469, 2011
The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin
Z Varasteh, U Rosenström, I Velikyan, B Mitran, M Altai, H Honarvar, ...
Molecules 19 (7), 10455-10472, 2014
Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with 99mTc, 111In, and 125I
C Hofström, A Orlova, M Altai, F Wångsell, T Gräslund, V Tolmachev
Journal of medicinal chemistry 54 (11), 3817-3826, 2011
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [99mTc(CO)3]+-Labeled …
C Hofström, M Altai, H Honarvar, J Strand, J Malmberg, ...
Journal of medicinal chemistry 56 (12), 4966-4974, 2013
Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors
H Honarvar, K Westerlund, M Altai, M Sandström, A Orlova, V Tolmachev, ...
Theranostics 6 (1), 93, 2016
Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors
M Altai, H Liu, H Ding, B Mitran, PH Edqvist, V Tolmachev, A Orlova, ...
Journal of controlled release 288, 84-95, 2018
Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule
A Orlova, M Malm, M Rosestedt, Z Varasteh, K Andersson, RK Selvaraju, ...
European journal of nuclear medicine and molecular imaging 41, 1450-1459, 2014
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in …
J Malmberg, A Perols, Z Varasteh, M Altai, A Braun, M Sandström, ...
European journal of nuclear medicine and molecular imaging 39, 481-492, 2012
Comparative evaluation of radioiodine and technetium-labeled DARPin 9_29 for radionuclide molecular imaging of HER2 expression in malignant tumors
A Vorobyeva, O Bragina, M Altai, B Mitran, A Orlova, A Shulga, ...
Contrast Media & Molecular Imaging 2018, 2018
Radionuclide therapy of HER2-expressing human xenografts using affibody-based peptide nucleic acid–mediated pretargeting: in vivo proof of principle
K Westerlund, M Altai, B Mitran, M Konijnenberg, M Oroujeni, C Atterby, ...
Journal of Nuclear Medicine 59 (7), 1092-1098, 2018
Feasibility of affibody-based bioorthogonal chemistry–mediated radionuclide pretargeting
M Altai, A Perols, M Tsourma, B Mitran, H Honarvar, M Robillard, ...
Journal of Nuclear Medicine 57 (3), 431-436, 2016
Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with 68Ga …
M Altai, J Strand, D Rosik, RK Selvaraju, A Eriksson Karlström, A Orlova, ...
Bioconjugate chemistry 24 (6), 1102-1109, 2013
Comparative evaluation of two DARPin variants: effect of affinity, size, and label on tumor targeting properties
S Deyev, A Vorobyeva, A Schulga, G Proshkina, R Guler, J Lofblom, ...
Molecular pharmaceutics 16 (3), 995-1008, 2019
In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors
M Altai, Z Varasteh, K Andersson, A Eek, O Boerman, A Orlova
Cancer Biotherapy and Radiopharmaceuticals 28 (3), 187-195, 2013
Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label
S Lindbo, J Garousi, B Mitran, M Altai, J Buijs, A Orlova, S Hober, ...
Journal of Nuclear Medicine 59 (1), 93-99, 2018
Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules
V Tolmachev, M Altai, M Sandström, A Perols, AE Karlström, ...
Bioconjugate chemistry 22 (5), 894-902, 2011
Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26
B Mitran, SS Rinne, MW Konijnenberg, T Maina, BA Nock, M Altai, ...
International Journal of Cancer 145 (12), 3347-3358, 2019
Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX: 1 affibody molecule
H HONARvAR, J Garousi, E Gunneriusson, I HöIDéN-GUTHENbERG, ...
International journal of oncology 46 (2), 513-520, 2015
Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with 18F …
D Rosik, A Thibblin, G Antoni, H Honarvar, J Strand, RK Selvaraju, M Altai, ...
Bioconjugate chemistry 25 (1), 82-92, 2014
The system can't perform the operation now. Try again later.
Articles 1–20